Melbourne, Australia: Australian company Cytomatrix has hired ex Bell Potter Life Sciences Investment Banker Mr. Michael Sistenich, as the Company expands its management team, fresh from a $6.4m capital raise.
Mr. Sistenich, as Head of Corporate Development, will lead, with Managing Director Mr. Benjamin Bergo, capital raising and major corporate transactions for the Company.
Mr. Sistenich led the life sciences investment banking practice at Bell Potter Securities for the past year, completing significant placements for Starpharma, Phosphagenics, Circadian Technologies and Avita Medical.
He brings with him over 18 years of experience as a healthcare specialist in international investment management and investment banking, including as a Director of International Equities and Head of Global Healthcare Investments at DWS Investments GmbH, Deutsche Bank Frankfurt, where he was directly responsible for over 6.5bn Euros of Healthcare Investments, and as the Senior Portfolio manager of the Meditor Cobra Fund, a Global Healthcare Long/Short Equity hedge fund where he grew assets from 30mn to 450mn Euros.
Of the move into an unlisted micro-cap company, Michael commented: “I am delighted to join the Cytomatrix team at such a critical juncture in its corporate transition. Cytomatrix is progressing at pace with its corporate development and I’m very excited to be able to bring my experience in the financial markets to such a promising emerging biotech company. I look forward to working closely with Ben and the whole Cytomatrix team in delivering value for the current shareholders and introducing the opportunity to many new potential investors.”
About Cytomatrix’s technology
Cytomatrix Ltd. is a public unlisted Australian, development stage company with innovative scaffold, proprietary biological factors and short nanofibre technologies, which have been developed to support the rapid and economic expansion of Haematopoietic Stem Cells (HSCs) for therapeutic use in a variety of bone marrow and chemotherapy related applications. The company was founded in 2007 by Associate Professor Mark Kirkland, who is also the Medical Director of the successful cord blood banking business Cell Care and Associate Professor at Deakin University.
The global market across cord blood transplant, bone marrow transplants and high dose chemotherapy patients is estimated to be in excess of USD $4 billion.
For further information please contact:
Media and investor relations
Ben Walsh bwalsh@buchanwe.com.au +612 9237 2801
Company
Ben Bergo
benjamin.bergo@cytomatrix.com.au
+61 407 558 723
Help employers find you! Check out all the jobs and post your resume.
Mr. Sistenich, as Head of Corporate Development, will lead, with Managing Director Mr. Benjamin Bergo, capital raising and major corporate transactions for the Company.
Mr. Sistenich led the life sciences investment banking practice at Bell Potter Securities for the past year, completing significant placements for Starpharma, Phosphagenics, Circadian Technologies and Avita Medical.
He brings with him over 18 years of experience as a healthcare specialist in international investment management and investment banking, including as a Director of International Equities and Head of Global Healthcare Investments at DWS Investments GmbH, Deutsche Bank Frankfurt, where he was directly responsible for over 6.5bn Euros of Healthcare Investments, and as the Senior Portfolio manager of the Meditor Cobra Fund, a Global Healthcare Long/Short Equity hedge fund where he grew assets from 30mn to 450mn Euros.
Of the move into an unlisted micro-cap company, Michael commented: “I am delighted to join the Cytomatrix team at such a critical juncture in its corporate transition. Cytomatrix is progressing at pace with its corporate development and I’m very excited to be able to bring my experience in the financial markets to such a promising emerging biotech company. I look forward to working closely with Ben and the whole Cytomatrix team in delivering value for the current shareholders and introducing the opportunity to many new potential investors.”
About Cytomatrix’s technology
Cytomatrix Ltd. is a public unlisted Australian, development stage company with innovative scaffold, proprietary biological factors and short nanofibre technologies, which have been developed to support the rapid and economic expansion of Haematopoietic Stem Cells (HSCs) for therapeutic use in a variety of bone marrow and chemotherapy related applications. The company was founded in 2007 by Associate Professor Mark Kirkland, who is also the Medical Director of the successful cord blood banking business Cell Care and Associate Professor at Deakin University.
The global market across cord blood transplant, bone marrow transplants and high dose chemotherapy patients is estimated to be in excess of USD $4 billion.
For further information please contact:
Media and investor relations
Ben Walsh bwalsh@buchanwe.com.au +612 9237 2801
Company
Ben Bergo
benjamin.bergo@cytomatrix.com.au
+61 407 558 723
Help employers find you! Check out all the jobs and post your resume.
